John W. Morgan

John W. Morgan

Auto-generated profile, based on publicly available information

John W. Morgan

Loma Linda University School of Public Health, Loma Linda, CA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BJBrice Jabo
Brice Jabo
JMJohn W Morgan
John W Morgan
MMMaria Elena Martinez
Maria Elena Martinez
MGMark Ghamsary
Mark Ghamsary
MWMatthew Wieduwilt
Matthew Wieduwilt
Identifying sociodemographic disparities in chemotherapy and hematopoietic cell transplantation (HCT) utilization for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) may improve survival for underserved populations. In this study, we incorporate neighborhood socioeconomic status (nSES), marital status, and distance from transplant center with previously studied factors to provide a comprehensive analysis of sociodemographic factors influencing treatments for ALL and AML. Using the California Cancer Registry, we performed a retrospective, population-based study of patients ≥15 years old with ALL (n = 3,221) or AML (n = 10,029) from 2003 through 2012. The effect of age, sex, race/ethnicity, marital status, nSES, and distance from nearest transplant center on receiving no treatment, chemotherapy alone, or chemotherapy then HCT was analyzed. No treatment, chemotherapy alone, or chemotherapy then HCT were received by 11%, 75%, and 14% of ALL patients and 36%, 53%, and 11% of AML patients, respectively. For ALL patients ≥60 years old, HCT utilization increased from 5% in 2005 to 9% in 2012 (p = 0.03). For AML patients ≥60 years old, chemotherapy utilization increased from 39% to 58% (p<0.001) and HCT utilization from 5% to 9% from 2005 to 2012 (p<0.001). Covariate-adjusted analysis revealed decreasing relative risk (RR) of chemotherapy with increasing age for both ALL and AML (trend p <0.001). Relative to non-Hispanic whites, lower HCT utilization occurred in Hispanic [ALL, RR = 0.80 (95% CI = 0.65–0.98); AML, RR = 0.86 (95% CI = 0.75–0.99)] and non-Hispanic black patients [ALL, RR = 0.40 (95% CI = 0.18–0.89); AML, RR = 0.60 (95% CI = 0.44–0.83)]. Compared to married patients, never married patients had a lower RR of receiving chemotherapy [ALL, RR = 0.96 (95% CI = 0.92–0.99); AML, RR = 0.94 (95% CI = 0.90–0.98)] or HCT [ALL, RR = 0.58 (95% CI = 0.47–0.71); AML, RR = 0.80 (95% CI = 0.70–0.90)]. Lower nSES quintiles predicted lower chemotherapy and HCT utilization for both ALL and AML (trend p <0.001). Older age, lower nSES, and being unmarried predicted lower utilization of chemotherapy and HCT among ALL and AML patients whereas having Hispanic or black race/ethnicity predicted lower rates of HCT. Addressing these disparities may increase utilization of curative therapies in underserved acute leukemia populations.

1 December 2007 in The Permanente Journal
Verified
Journal Article
Closed access
CSCharles S Salemi
Charles S Salemi
TJTimothy D Jenkins
Timothy D Jenkins
AAAndres Aguirre
Andres Aguirre
ACAnnie Cao
Annie Cao
GVGisela Villaruel
Gisela Villaruel
ASAndrew Simental
Andrew Simental
We studied antibiotic use prior to the onset of Clostridium difficile colitis (CDC) and time interval between onset of gastrointestinal symptoms and diagnosis for two historical time periods with separate comparisons for inpatients and outpatients to determine whether time to diagnosis had decreased and whether previous metronidazole use is associated with CDC. We performed a retrospective chart review of adult patients (those 18 years or older) with positive findings on Clostridium difficile (CD) stool toxin tests performed at a Kaiser Permanente Southern California medical center. Independent assessments were compared for 1997-1998 and for 2004 time periods. These assessments used similar enrollment and exclusion criterion. Study populations were evaluated for previous antibiotic use and to determine time from clinical presentation of symptoms to diagnosis of CDC during each of the time periods, with assessments made separately for inpatients and outpatients. Findings showed a reduction in the average time from symptom presentation to diagnosis among outpatients with CDC from 17 days in the first time period (1997-1998) to ten days during the second time period (2004). No significant difference in the average time from symptom presentation to diagnosis of CDC was evident among inpatients (5.33 days for 1997-1998 and 6.00 days for 2004). Multiple antibiotic use prior to diagnosis of CDC was evident among both outpatients and inpatients in this study. Metronidazole had been used prior to the onset of CDC in approximately 15% of cases. The time from symptom onset to a CDC diagnosis decreased by seven days between the 1997-1998 and 2004 time periods among outpatients in this health care setting. Previous metronidazole use appeared to be associated with some cases of CDC.

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BJBrice Jabo
Brice Jabo
JMJohn W. Morgan
John W. Morgan
MAMayada A. Aljehani
Mayada A. Aljehani
MSMatthew J Selleck
Matthew J Selleck
ALAlbert Y. Lin
Albert Y. Lin
E15575 Background: Gastric cancer (GC) mortality remains high, with a 5-year survival of 30 percent. For patients with resectable GC, mortality varies depending on both patient and tumor characteristics. The current study sought to develop a web-based prognostic model to assist patients and health care providers in decision making regarding either surgery-only or adjuvant chemoradiotherapy (CRT). Methods: California SEER data was used and records, including demographic, pathologic, and treatment information, for 2,583 patients diagnosed with stage IB to III GC and treated with either surgery only or adjuvant CRT from 2006 to 2013 were retrieved. Purposeful selection using Cox regression model was used to identify important mortality predictors. Additionally, with simple random sampling, 70% of the data were assigned to the training set and the remaining 30% were assigned to the test set. Furthermore, generalized boosted classification model was trained using the training set and validated using the test set. Area under the curve (AUC) of the receiver operating characteristic (ROC), sensitivity, specificity and accuracy were determined for 5- and 10-year mortality. Results: The median survival was 33 months for patients in the training set, and 32 for the test set. Predictors included in the model were age, ethnicity (Asian/other, Hispanic, non-Hispanic black and non-Hispanic white), T-stage, histology (intestinal, diffuse and other), presence of signet ring (yes/no), proximal location (yes/no), lymph node ratio, and CRT following surgery (yes/no). Validation of the model on the test set showed as follows: AUC, sensitivity, specificity and accuracy of 0.78(95%CI = 0.75,0.82), 0.75, 0.65 and 0.70 for 5-year survival and 0.77(95%CI = 0.74,0.80), 0.79, 0.55 and 0.70 for 10-year survival. Conclusions: The proposed web-based prognostic tool using readily available patient and tumor characteristic provides validated and personalized prognostic information to aide clinicians and patients in GC adjuvant treatment decision process. [Table: see text]

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ALAlbert Y. Lin
Albert Y. Lin
BJBrice Jabo
Brice Jabo
LJLiang Ji
Liang Ji
JMJohn S. Macdonald
John S. Macdonald
PRPeter Ravdin
Peter Ravdin
JMJohn W. Morgan
John W. Morgan
E15569 Background: Results from SWOG9008/ Intergroup 0116 trial, published in 2001, documented that CRT improved survival for GC patients in the adjuvant setting and established postoperative CRT as the standard of care. An updated analysis, published in 2012, showed sustained benefits of adjuvant CRT with a median follow-up of 10.3 years. Our study was initiated to examine if the persistent benefits would be applicable to a population-based setting. Methods: Data from the statewide California Cancer Registry (CCR) database for patients diagnosed with stage IIIIC GC, age 24-88 years from 2004-2012 were analyzed and compared with individual data from SWOG9008 for overall survival (OS) using Cox regression analysis. Covariates included age, sex, race/ethnicity, T-stage, number of positive lymph nodes, diffuse vs. intestinal histology subtypes and the primary tumor location. Results: Among the 2,046 CCR patients who underwent GC resection, 1,570 received surgery only, while 476 (23.3%) also received CRT. OS benefits were evident for patients receiving combined modality treatment versus surgery alone for both SWOG9008 study subjects and CCR patients [HR = 0.72 (95%CI = 0.59-0.87) and HR = 0.54(95%CI = 0.45-0.63), respectively]. Other results include evidence of significant OS benefits for patients who are younger, diagnosed with smaller T-size, have fewer positive lymph nodes, and those with non-diffuse histology. Percentage of patients who were treated with CRT was: 19% (2004), 27% (2005), 26% (2006), 16% (2007), 18% (2008), 20% (2009), 27% (2010), 26% (2011), and 27% (2012) (P < 0.05; Cochran–Armitage test for trend). Conclusions: The OS benefits of CRT in the adjuvant setting for GC patients were in concordance between SWOG9008 patients and the CCR patients, as were prognostic factors. The proportion of patients who underwent adjuvant CRT declined for 2007, concomitant with publication of findings from other studies suggesting benefits from postoperative or perioperative chemotherapy. However, use of CRT increased during ensuing years and eventually stabilized at the pre-2007 level. Overall, only about 25% of CCR patients received CRT adjuvant to surgery from 2004-2012.